Screening for lung cancer: what have we learned?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 24555588.
- Also identified by DOI 10.2214/AJR.13.11540.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The purposes of this article are to briefly review the history of lung cancer screening, discuss the results and implications of the National Lung Screening Trial, and address some of the questions that remain since the publication of this landmark study. Lung cancer remains the leading cause of cancer-related death in the United States and the world. The National Lung Screening Trial showed a 20% reduction in lung cancer mortality among individuals at high risk undergoing low-dose CT. The findings opened the door for clinical lung cancer screening and publication of lung cancer screening guidelines. However, many questions remain, including whom to screen, how often, and for how long. Furthermore, costs and effects on the health care system remain unclear.
Medical subject headings
- Early Detection of Cancer
- Evidence-Based Medicine
- Lung Neoplasms
- Radiography, Thoracic
- Tomography, X-Ray Computed